On October 31, 2024, the European Commission (EC) fined Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe BV (Teva) EUR462.6 million for abusing a dominant position in several EU Member States on the...more
11/6/2024
/ Antitrust Violations ,
Competition ,
Corporate Counsel ,
Disparagement ,
EU ,
European Commission ,
Fines ,
Infringement ,
Innovation Patent ,
Patents ,
Pharmaceutical Industry ,
Technology Sector ,
Teva Pharmaceuticals ,
UK
On 10 October 2022, the European Commission (EC) sent a Statement of Objections to Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe BV (Teva). The EC has provisionally found that Teva abused its dominant...more